evidence of the lesion; evidence of its disappearance after an adequate period on a gluten free diet; and evidence of its recurrence after the reintroduction of gluten into the diet. Such a procedure, which seems to be widely accepted in Europe,2 is probably optimal for a firm diagnosis, but has several drawbacks, particularly in the light of new developments that have since taken place. Firstly, the time required for the final diagnosis is unduly long (three years on average); secondly, it does not take into account the variability in clinical expression of the disease; thirdly, it does not take into account the fact that after the age of 2 years it is highly unusual for subtotal villous atroph! to be caused by diseases other than coeliac disease ; and, fourthly, it means re-exposing a child to the offending agent in order to reproduce the mucosal damage. Furthermore, even this challenge (which is now known to be potentially harmful to the child's growing potential3 4) might be inconclusive, as evidence is now mounting that relapse may take longer than two years.2 5 6 It is therefore not surprising that several Finally, the specificity of antigliadin antibodies when tested against healthy controls is high. We believe that these conclusions are true, despite the fact that the methods used differed among the centres (enzyme linked immunosorbent assay (ELISA) in most, immunofluorescence in a few). Our conclusion is based on the large sample size, and the consistency of the results compared with most other reported series. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Another test widely used for the diagnosis of coeliac disease is the one hour blood D-xylose absorption test. When considered alone in our patients, this test agreed with the jejunal histology in 70%. When the xylose test was used in combination with estimation of antigliadin antibodies, however, Considering the time elapsing between onset of symptoms and first biopsy (on average 3-8 years in the series of 94 'atypical' patients, 3-6 in the 44 late onset patients), it is evident that the mean age is much higher-6-7 years for the former group of patients with coeliac disease, 9*8 for the latter. At these ages, and in our geographical area, there is practically no differential diagnosis for subtotal villous atrophy responding to gluten withdrawal. A particular subgroup of 'atypical' patients with coeliac disease comprises those affected by dermatitis herpetiformis (Duhring's disease). They can be diagnosed with full confidence from a skin biopsy specimen by an experienced dermatologist,'4 thus obviating the need for intestinal biopsy.
Diagnostic importance of the initial finding of subtotal villous atrophy in a child suspected of having coeliac disease From the clinical records from 30 centres, we found that 3293 children underwent intestinal biopsy for suspected coeliac disease, and were found to have crypt hyperplastic subtotal villous atrophy. Among them, 3138 (95%) were eventually diagnosed as having coeliac disease after completing the full diagnostic procedure. It should be emphasised that 2400 of them strictly followed the diagnostic phases of the ESPGAN protocol; the remaining 738 patients were diagnosed as having coeliac disease by 'simplified' diagnostic schemes, most of them omitting the second biopsy (table 3) . Interestingly, the percentage of patients eventually diagnosed as having coeliac disease was no different among those who followed the ESPGAN protocol (95%) and those who did not (95-8%), suggesting an overlapping diagnostic accuracy between the rigid protocol and the more flexible attitude.
Focusing on the 155 patients (4.7%) in whom the diagnosis of coeliac disease was unconfirmed at the end of the diagnostic procedure, the following observations can be made: (i) the most common single diagnosis was cows' milk sensitive enteropathy (n=32, 20-6%), followed by transient gluten intolerance (n=24, 15.5%); (ii) the mean age of the patients at the time of first biopsy was 8 months, further highlighting the fact that the differential diagnosis of coeliac disease is essentially a problem of infancy; (iii) the data refer to patients that were, in most cases, seen at a time when estimation of antigliadin antibodies was not possible. It is therefore likely that that estimation could have improved the diagnostic value of the first biopsy.
These observations indicate that when facing a child whose history is consistent with coeliac disease and whose first biopsy specimen shows an unequivocal crypt hyperplastic subtotal villous atrophy, in our geographical area one has at least a 95% chance that one is dealing with coeliac disease: a diagnostic accuracy not too frequently found in paediatric practice. Furthermore, it is clear that adding the diagnostic weight of estimation of HLA and anti- Table 4 shows the data concerning age at diagnosis and duration of the diagnostic phases in 361 patients with coeliac disease; these are the 15 most recently diagnosed patients from each centre. The mean age of diagnosis (3-2 years) seems somewhat higher than in the past, in accordance with the present trend of the disease as reported by others.15 Mean duration of the gluten free diet seems quite long, even longer than that recommended by the ESPGAN protocol, thus increasing the likelihood of poor compliance to the diet and delaying the time to conclusive diagnosis. Most important, however, is the duration of challenge (seven months), which seems too long. In most patients the mucosal relapse occurs within three months,16 17 although individual variations in the speed of mucosal relapses are well recognised, and in the occasional patient a particularly long time may elapse.5
In any case, prolonging the duration of the challenge in the patients with coeliac disease does not seem to be of any benefit: the histological, clinical, and biochemical data from 195 patients with coeliac disease show that the bulk of laboratory results (excluding estimation of antigliadin antibodies) and the clinical response do not correlate with histological signs of relapse. Only in 48-8% of our cases did such a correlation exist, similar to what has previously been reported by others. 6 16 17 Thus prolonging gluten challenge does not help in providing clear cut evidence on which to decide the time for biopsy and in addition has harmful effects on the child's weight and growth. Recent evidence, on the other hand, indicates that antigliadin antibodies rise within a few weeks of the reintroduction of gluten. 18 Thus by monitoring the rise in antigliadin antibodies, most challenges may be stopped after 60 days. 8 If we consider that 95% of the patients are already correctly diagnosed after the first biopsy, and that this figure may only increase by the use of estimations of antigliadin antibodies, to link the final diagnosis to the outcome of the challenge might actually result in underdiagnosis of the disease. On one hand, the support offered by clinical and laboratory data is poor, and on the other hand, it is well known that a number of patients do develop the mucosal lesion late.5 6 Finally, it must not be forgotten that a prolonged challenge, particularly during periods of increased growth (infancy and adolescence), may interfere with linear growth.34 The bulk of this evidence would then suggest that a gluten challenge is not necessary for diagnosis and may actually prove to be harmful.
Conclusions
After having carefully evaluated and thoroughly discussed all the evidence that has been outlined briefly above, the Working Group for Gastroenterology came to the following conclusions: (1) in many instances of suspected coeliac disease (and in our geographical area) the diagnostic approach may differ from that recommended in the ESPGAN protocol. It must be firmly stated, however, that at present no diagnosis of coeliac disease can be made without the characteristic histological picture of the duodenal-jejunal mucosa. (2) In cases presenting with a history and clinical picture suggestive of coeliac disease, laboratory data (including antigliadin antibodies) consistent with coeliac disease, a clear histological picture of a crypt hyperplastic subtotal villous atrophy, an obvious clinical and laboratory response to the gluten free diet, and as long as the diagnosis of cows' milk sensitive enteropathy can be ruled out, the definitive diagnosis of coeliac disease can be made. On this basis, gluten must be permanently excluded from the diet, and regular follow up should be instituted.
Whenever the diagnosis is uncertain on the basis of history or clinical or laboratory evidence, or both, or the appearance of the mucosa at initial biopsy is considered doubtful, strict adherence to the ESPGAN protocol is recommended (including gluten challenge to be carried out at an early age), with the possible exception that the second biopsy may be omitted, provided that all pertinent data (including estimation of antigliadin antibodies) are in agreement.
Spontaneous gluten reintroduction is to be avoided by all costs. Whenever, in order to prevent it, or in accordance with family pressure, it is decided to perform a medically supervised gluten challenge, it is recommended that such a challenge should not be done during the pubertal spurt of infantile growth and that the diet containing gluten is maintained for no longer than three months in the first instance. Evaluation of relapse may, but does not necessarily have to, be confirmed histologically; such confirmation may not be needed when clinical and laboratory evidence (including a rise in antigliadin antibodies titre) is clear.
These considerations and recommendations are reported as a matter for further discussion and in the hope that they will stimulate comments and criticism from all paediatricians who take part in investigation or clinical management, or both, of young patients with coeliac disease.
Correspondence to Professor S Guandalini, Dipartimento di Pediatria, 2a Facolta' di Medicina, Universita' di Napoli, Via S Pansini 5, 80131 Napoli, Italy. The 'cause' of coeliac disease is not yet known in molecular terms. The diagnosis of coeliac disease remains empirical and is currently based on two well established facts. The first is that gluten causes a malabsorption syndrome with small bowel enteropathy in susceptible subjects.1 Secondly, withdrawal of gluten from the diet leads to complete restoration to normal of the patient and his intestinal mucosa.2
A third important contribution to our thinking about coeliac disease was provided by the (then) European Society for Paediatric Gastroenterology (ESPGA) in its publication of the 'Interlaken criteria'. In these criteria, coeliac disease was affirmed to be a permanent condition of gluten intolerance, and it was implied that, in order to substantiate an initial diagnosis of coeliac disease, the permanence (or at least persistence) of gluten intolerance should be confirmed in each individual
